I think the reversal has already started. The orphan drug designation speaks to the sentiment of the FDA with regards to the potential of the AML trial. It’s basically stating that MRKR’s technology is unique and has the potential to be the sole treatment option for a demographic of patients. Wall Street could acknowledge this or any other positive news by buying, shorting, or a combination of both. The technical chart is telling a lot of traders that this thing is ready for a big move up. That could play a huge role in getting this thing back on track. We should also be hearing from our friends at the Mayo Clinic sometime in the next six months.
Market Data 
Markets 
AI
